Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
緒言
悪性腫瘍放射線治療の歴史は,いかにして腫瘍に多くの線量を,一方,正常組織にはいかに少い線量を与えるかという努力の軌跡であろう。この意味からも近年放射線増感物質が注目されているのも当然といえる。
そのうち,最近脳外科領域で注目されているものに,ピリミジン環の5の位置にBrを持った5—bromodeox—yuridine (BUdR)がある。この放射線増感性が,佐野1)らによりBAR療法として脳腫瘍治療に応用されて約3年半になる。今や,その正しい評価の下されるべき段階であるということができよう。かかる意味から,私共がBAR療法を行なった悪性神経膠腫頭蓋外転移例について報告し,諸賢の御批判をあおぎたい。
The efiect of BUdR with oadiation therapy was observed on a case of malignant astrocytoma with extracranial metastasis.
31 year-old male of the right rarieto-malignant astrocytoma developed the extracranial metastasis to his right neck, for which the right carotid arterial continuous infusion-radiation therapy (BAR) was performed. BUdR of 29. 5 gm and methotrexate of 26 mg were infused, resulting the tumor disappear-ance macrospectively when the BAR therapy was completed.
However, this patient again developed the mata-stasis to the right axillar and chest, for which BUdR and methotrexate were infused locally followed by LINAC radiation of 1000 rads (single exposure).
This resulted also the disappearance of the tumors macrospectively. However, the histological exami-nation showed that some of the tumor cells were still survived. But, its DNA contents were lower than the tumor cells without BUdR infusion.
All of these datas suggests the effect of BUdR as the radiosensitizer for glioma therapy. And this case also elicited the good result of locally applied BUdR
We concluded the BUdR therapy was worth for trial of glioma therapy.
Copyright © 1970, Igaku-Shoin Ltd. All rights reserved.